Discover InVEST44
Our newly launched panel of well-regarded targets to de-risk you early stage safety and toxicology programs

  • Ten-Day Turnaround
  • Timely Results
  • Cost-Efficiency
  • Expert Support
  • Quality Data
Discover InVEST44

Premium Drug Discovery Services

Our clients are seeking answers in their quest to discover effective treatments for patients. Finding these answers is our mission as a CRO. Our method is to accelerate the drug discovery process with the widest possible range of assays and services but also to maintain an integrated view of the journey to a lead drug candidate. We strive to provide excellent data, delivered in a timely, collaborative manner by outstanding scientists. Who are we? We’re your partner.

What people are saying

Reaction Biology Europe has provided their services for several projects with us, including establishing an orthotopic tumor model and PK/PD studies. I was very impressed, not only by their level of expertise and professionalism but also by their enthusiasm and drive to deliver. The insightful advice they provide has been instrumental to our successes and their collegial and “can do” attitude make them a pleasure to team up with!

Prof Matthias Klugmann
Scientific Expert at Boehringer-Ingelheim

Meet Us at Our Next Event

San Diego, CA, USA
San Diego, CA, USA
-

Drug Discovery Chemistry

Visit us in San Diego at Booth 306

Schedule a meeting
Chicago, IL, USA
Chicago, IL, USA
-

AACR 2025

Visit the Reaction Biology team at Booth 1242

Schedule a meeting

Latest News

Bioassay GmbH, a Reaction Biology Company, Obtains GMP Manufacturing License for Quality Control Testing on Veterinary Products

Bioassay GmbH, a leading provider of bioanalytical testing solutions, is pleased to announce that it has successfully obtained a veterinary Good Manufacturing Practice (GMP) license according to Art.

Reaction Biology Launches Innovative Offering Within Its Kinase Testing Platform and Presents New Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Reaction Biology (“Reaction” or the “Company”), an industry-leading provider of drug discovery and development services, today announced that it will feature its recently launched HotSpot™ ATP-Max KinomeScreen at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 7-10, 2024, in San Diego, California.

Reaction Biology to Present Data at AACR 2023 Showcasing Expansive Capabilities in Immuno-Oncology Drug Discovery and Development

~ New Data will be Presented on the Company’s Innovative Assay Technologies, Preclinical Profiling Models and Proprietary Screening Platforms ~

~ Reaction Biology will be at Booth #1527 in the AACR 2023 Exhibit Hall ~